Two major players in the weight-loss solutions space are merging. Obalon Therapeutics and ReShape are both combining in an all-stock transaction. The merger comes almost a year after Obalon announced it was seeking strategic alternatives.
Boston Scientific said it is in agreement to acquire Preventice Solutions, a mobile cardiac health solutions and services specialist, for an upfront payment of $925 million with the potential for $300 million in milestones.
Thermo Fisher Scientific is diving a bit deeper into point-of-care coronavirus testing with its latest acquisition. The Waltham, MA-based company is acquiring Mesa Biotech for about $450 million in cash and could pay up to $100 million in milestones following the close of the deal. Plans call for the deal to close at the end of 1Q21.
Hillrom is gaining greater access into the ambulatory cardiac monitoring space with some new M&A. The Chicago, IL-based company is set to acquire Bardy Diagnostics (BardyDx) for $375 million with future potential payments based on the achievement of commercial milestones. The deal is set to close in 2Q21.